92.5 USD
+1.04 (+1.14%)
92.5 USD
0 (0%)
Taking everything into account, BNTX scores 3 out of 10 in our fundamental rating. BNTX was compared to 531 industry peers in the Biotechnology industry. BNTX has an average financial health and profitability rating. BNTX is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
BNTX had negative earnings in the past year.
In the past year BNTX has reported a negative cash flow from operations.
Of the past 5 years BNTX 4 years were profitable.
BNTX had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
With an excellent Return On Assets value of -2.68%, BNTX belongs to the best of the industry, outperforming 87.03% of the companies in the same industry.
BNTX has a Return On Equity of -3.09%. This is amongst the best in the industry. BNTX outperforms 89.47% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.68% | ||
| ROE | -3.09% | ||
| ROIC | N/A |
ROA(3y)13.87%
ROA(5y)21.46%
ROE(3y)16.07%
ROE(5y)27.17%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BNTX has a Gross Margin of 85.62%. This is amongst the best in the industry. BNTX outperforms 88.35% of its industry peers.
In the last couple of years the Gross Margin of BNTX has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for BNTX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 85.62% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.1%
GM growth 5Y0.34%
2. Health
2.1 Basic Checks
BNTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BNTX has been increased compared to 1 year ago.
BNTX has more shares outstanding than it did 5 years ago.
BNTX has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 5.96 indicates that BNTX is not in any danger for bankruptcy at the moment.
BNTX has a Altman-Z score of 5.96. This is in the better half of the industry: BNTX outperforms 74.62% of its industry peers.
BNTX has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.01, BNTX is in line with its industry, outperforming 44.17% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 5.96 |
ROIC/WACCN/A
WACC7.23%
2.3 Liquidity
BNTX has a Current Ratio of 7.12. This indicates that BNTX is financially healthy and has no problem in meeting its short term obligations.
BNTX has a better Current ratio (7.12) than 70.30% of its industry peers.
BNTX has a Quick Ratio of 7.02. This indicates that BNTX is financially healthy and has no problem in meeting its short term obligations.
BNTX's Quick ratio of 7.02 is fine compared to the rest of the industry. BNTX outperforms 70.30% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.12 | ||
| Quick Ratio | 7.02 |
3. Growth
3.1 Past
The earnings per share for BNTX have decreased strongly by -20.92% in the last year.
Looking at the last year, BNTX shows a small growth in Revenue. The Revenue has grown by 3.70% in the last year.
The Revenue has been growing by 90.73% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-20.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-114.81%
Revenue 1Y (TTM)3.7%
Revenue growth 3Y-47.47%
Revenue growth 5Y90.73%
Sales Q2Q%22.02%
3.2 Future
Based on estimates for the next years, BNTX will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.03% on average per year.
Based on estimates for the next years, BNTX will show a small growth in Revenue. The Revenue will grow by 2.18% on average per year.
EPS Next Y-16.98%
EPS Next 2Y-6.87%
EPS Next 3Y-3.32%
EPS Next 5Y14.03%
Revenue Next Year4.3%
Revenue Next 2Y0.77%
Revenue Next 3Y1.01%
Revenue Next 5Y2.18%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for BNTX. In the last year negative earnings were reported.
Also next year BNTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
BNTX's earnings are expected to decrease with -3.32% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-6.87%
EPS Next 3Y-3.32%
5. Dividend
5.1 Amount
BNTX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
92.5
+1.04 (+1.14%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners22.75%
Inst Owner Change-2.53%
Ins Owners2.11%
Ins Owner ChangeN/A
Market Cap22.24B
Revenue(TTM)3.15B
Net Income(TTM)-571.60M
Analysts80.71
Price Target139.7 (51.03%)
Short Float %6.55%
Short Ratio6.18
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)33.13%
Min EPS beat(2)21.85%
Max EPS beat(2)44.42%
EPS beat(4)4
Avg EPS beat(4)77.6%
Min EPS beat(4)18.78%
Max EPS beat(4)225.36%
EPS beat(8)5
Avg EPS beat(8)44.65%
EPS beat(12)9
Avg EPS beat(12)207.14%
EPS beat(16)12
Avg EPS beat(16)164.98%
Revenue beat(2)2
Avg Revenue beat(2)63.4%
Min Revenue beat(2)55.06%
Max Revenue beat(2)71.75%
Revenue beat(4)4
Avg Revenue beat(4)33.69%
Min Revenue beat(4)1.02%
Max Revenue beat(4)71.75%
Revenue beat(8)5
Avg Revenue beat(8)18.96%
Revenue beat(12)6
Avg Revenue beat(12)5.54%
Revenue beat(16)9
Avg Revenue beat(16)12.1%
PT rev (1m)1.07%
PT rev (3m)0.31%
EPS NQ rev (1m)80.22%
EPS NQ rev (3m)97.78%
EPS NY rev (1m)32.36%
EPS NY rev (3m)35.12%
Revenue NQ rev (1m)-0.19%
Revenue NQ rev (3m)-14.3%
Revenue NY rev (1m)24.33%
Revenue NY rev (3m)29.77%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 6.02 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.03 | ||
| P/tB | 1.14 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.78
EYN/A
EPS(NY)-3.72
Fwd EYN/A
FCF(TTM)-5.33
FCFYN/A
OCF(TTM)-1.54
OCFYN/A
SpS15.36
BVpS90
TBVpS81.49
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.68% | ||
| ROE | -3.09% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 85.62% | ||
| FCFM | N/A |
ROA(3y)13.87%
ROA(5y)21.46%
ROE(3y)16.07%
ROE(5y)27.17%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.1%
GM growth 5Y0.34%
F-Score3
Asset Turnover0.15
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 202.92% | ||
| Cap/Sales | 24.68% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 7.12 | ||
| Quick Ratio | 7.02 | ||
| Altman-Z | 5.96 |
F-Score3
WACC7.23%
ROIC/WACCN/A
Cap/Depr(3y)277.19%
Cap/Depr(5y)250.97%
Cap/Sales(3y)12.34%
Cap/Sales(5y)11.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-20.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-114.81%
EPS Next Y-16.98%
EPS Next 2Y-6.87%
EPS Next 3Y-3.32%
EPS Next 5Y14.03%
Revenue 1Y (TTM)3.7%
Revenue growth 3Y-47.47%
Revenue growth 5Y90.73%
Sales Q2Q%22.02%
Revenue Next Year4.3%
Revenue Next 2Y0.77%
Revenue Next 3Y1.01%
Revenue Next 5Y2.18%
EBIT growth 1Y-6.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year40.4%
EBIT Next 3Y12.9%
EBIT Next 5Y19.79%
FCF growth 1Y-123.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-105.92%
OCF growth 3Y-38.43%
OCF growth 5YN/A
BIONTECH SE-ADR / BNTX FAQ
Can you provide the ChartMill fundamental rating for BIONTECH SE-ADR?
ChartMill assigns a fundamental rating of 3 / 10 to BNTX.
Can you provide the valuation status for BIONTECH SE-ADR?
ChartMill assigns a valuation rating of 0 / 10 to BIONTECH SE-ADR (BNTX). This can be considered as Overvalued.
How profitable is BIONTECH SE-ADR (BNTX) stock?
BIONTECH SE-ADR (BNTX) has a profitability rating of 4 / 10.
How financially healthy is BIONTECH SE-ADR?
The financial health rating of BIONTECH SE-ADR (BNTX) is 5 / 10.
Can you provide the expected EPS growth for BNTX stock?
The Earnings per Share (EPS) of BIONTECH SE-ADR (BNTX) is expected to decline by -16.98% in the next year.